747 related articles for article (PubMed ID: 32406563)
1. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
2. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.
Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P
Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773
[No Abstract] [Full Text] [Related]
4. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
5. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.
Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J
Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720
[TBL] [Abstract][Full Text] [Related]
6. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
7. Subclassifying triple-negative breast cancers and its potential clinical utility.
Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
[TBL] [Abstract][Full Text] [Related]
8. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Fan L; Wang ZH; Ma LX; Wu SY; Wu J; Yu KD; Sui XY; Xu Y; Liu XY; Chen L; Zhang WJ; Jin X; Xiao Q; Shui RH; Xiao Y; Wang H; Yang YS; Huang XY; Cao AY; Li JJ; Di GH; Liu GY; Yang WT; Hu X; Xia Y; Liang QN; Jiang YZ; Shao ZM
Lancet Oncol; 2024 Feb; 25(2):184-197. PubMed ID: 38211606
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
11. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
Yoo TK; Kang J; Lee A; Chae BJ
Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
[TBL] [Abstract][Full Text] [Related]
12. Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers.
Kumar S; Bal A; Das A; Bhattacharyya S; Laroiya I; Khare S; Singh G
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):251-257. PubMed ID: 33337632
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
Mod Pathol; 2024 May; 37(7):100517. PubMed ID: 38763422
[TBL] [Abstract][Full Text] [Related]
14. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
[TBL] [Abstract][Full Text] [Related]
15. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
16. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes.
Kim NI; Park MH; Cho N; Lee JS
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):246-256. PubMed ID: 35384874
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
20. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]